GLP-1 biohacking claims on TikTok: what holds up?

What did @barrythebiohacker actually say?

Barry described tesofensine as a non-peptide compound originally developed as an antidepressant in a Danish clinical program. He claimed it produced "a 10% reduction in body weight" as an incidental finding, that it improved mood, energy, and focus, and that it's typically dosed at 500 micrograms daily. He framed it as a pill-based alternative to GLP-1 medications, which he noted can produce 18-24% weight loss. His overall pitch was that tesofensine is an accessible, multi-benefit compound for people who want weight loss without injections.

To his credit, he got the origin story roughly right. Tesofensine was indeed investigated in Europe as a potential CNS treatment before researchers noticed significant weight loss in trial participants. He also correctly contextualized 10% body weight loss as clinically meaningful, even if it's less dramatic than what tirzepatide trials have shown. But there's enough missing from this picture that it matters.

Does the science back this up?

The 10% weight loss figure is real, but it comes from a single Phase 2 trial that's now over 15 years old, and tesofensine has never cleared Phase 3 or received regulatory approval anywhere.

The key study here is Astrup et al. (2008, The Lancet), a randomized controlled trial in which participants taking 1.0 mg tesofensine lost roughly 10.6% of body weight over 24 weeks. That's a real signal. The 0.5 mg dose, which is close to what Barry recommends, produced about 8.2% weight loss in the same trial. Those are legitimately interesting numbers for an oral compound.

The mechanism is worth understanding: tesofensine is a triple monoamine reuptake inhibitor. It blocks the reuptake of dopamine, norepinephrine, and serotonin simultaneously. That's why it affects mood and energy, but it's also why the cardiovascular side effect profile in that same Lancet trial raised enough concern to stall development. Participants on higher doses showed meaningful increases in heart rate and blood pressure. A follow-up study by Sjödin et al. (2010, Obesity) confirmed the weight effects but also reinforced the cardiovascular signal. That's not a footnote. It's the reason this drug never made it to market.

What did they get wrong (or right)?

Barry got the mechanism category right and the weight loss ballpark right. Where the video falls short is in what it leaves out entirely.

Tesofensine is not approved by the FDA, EMA, or any major regulatory body. Calling it something you just "take as a pill" glosses over the fact that it's only available through unregulated research chemical or grey-market channels. That's a significant omission when you're broadcasting to 6,800 people who may act on this.

The cardiovascular concerns from the Astrup 2008 trial were serious enough that NeuroSearch, the Danish company behind the drug, discontinued its primary development program. Barry framed the Danish clinical research as a proof-of-concept success story, which is partially true, but left out why it didn't go further.

• The claim about mood improvement is plausible given the mechanism, but no tesofensine study has been specifically designed or powered to measure antidepressant efficacy in a way that meets modern standards.
• His dosing figures of 250 and 500 micrograms do correspond to doses used in research, but framing these as general guidance is irresponsible without flagging the cardiovascular monitoring those trials included.
• The comparison to GLP-1 weight loss percentages is fair as a rough benchmark, but the safety and long-term data behind semaglutide and tirzepatide are vastly more developed.

What should you actually know?

Tesofensine is a pharmacologically interesting compound with real weight loss data behind it, but calling it an alternative to GLP-1 therapy without discussing its regulatory status or cardiovascular profile is a disservice to anyone watching.

The honest picture: one Phase 2 trial showed meaningful weight loss, but the drug stalled in development partly due to a concerning heart rate and blood pressure profile. It has not been through the kind of large-scale, long-term safety evaluation that approved weight loss medications have. Anyone considering it is operating well outside the safety net of regulated medicine.

If you're interested in non-injection options for weight management, oral semaglutide (Rybelsus) is FDA-approved and has actual long-term cardiovascular outcome data. That's a conversation worth having with a licensed clinician, not a TikTok comment section.

Tesofensine may eventually find a place in medicine. The science isn't garbage. But "where do I sign up" is not the right response to a compound that's never cleared a Phase 3 trial and has known cardiovascular effects.